Advertisement

Intravenous Thrombolysis

  • Vasudha Singhal
  • Jaya Wanchoo
Chapter

Abstract

Acute ischemic stroke is a leading cause of disability worldwide. It is caused by a thrombus that blocks the flow of blood in a vessel of the brain. Early reperfusion therapy to restore blood flow by lysing the thrombus may reduce the volume of cerebral tissue irreversibly damaged. Intravenous thrombolytic drugs, particularly alteplase, have become the standard of treatment in acute ischemic stroke. With various randomized trials and increasing level of evidence, the eligibility criteria for the use of intravenous alteplase have been streamlined, thereby reducing the risks associated with this therapy, most notably symptomatic intracranial hemorrhage.

Keywords

Acute ischemic stroke Thrombolysis Alteplase Tissue plasminogen activator 

References

  1. 1.
    Sacco RL, Kasner SE, Broderick JP, et al. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44:2064–89.PubMedCrossRefGoogle Scholar
  2. 2.
    Feigin VL, Norrving B, Mensah GA. Global Burden of Stroke. Circ Res. 2017;120(3):439–48.PubMedCrossRefGoogle Scholar
  3. 3.
    Fisher M, Ginsberg M. Current concepts of the ischemic penumbra. Stroke. 2004;35:2657–8.CrossRefGoogle Scholar
  4. 4.
    Guadagno JV, Jones PS, Aigbirhio FI, Wang D, Fryer TD, Day DJ, et al. Selective neuronal loss in rescued penumbra relates to initial hypoperfusion. Brain. 2008;131(Pt 10):2666–78.PubMedCrossRefGoogle Scholar
  5. 5.
    Sussman BJ, Fitch TS. Thrombolysis with fibrinolysin in cerebral arterial occlusion. JAMA. 1958;167(14):1705–9.CrossRefGoogle Scholar
  6. 6.
    Donnan GA, Davis SM, Chambers BR, Gates PC, Hankey GJ, McNeil JJ, Rosen D, Stewart-Wynne EG, Tuck RR, for the Australian Streptokinase (ASK) Trial Study Group. Streptokinase for acute ischaemic stroke with relationship to time of administration. JAMA. 1996;276:966.CrossRefGoogle Scholar
  7. 7.
    Multicentre Acute Stroke Trial—Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin and combination of both in treatment of acute ischaemic stroke. Lancet. 1995;346:1509–14.CrossRefGoogle Scholar
  8. 8.
    Multicenter Acute Stroke Trial—Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med. 1996;335:145–50.CrossRefGoogle Scholar
  9. 9.
    Brott TG, Haley EC, Levy DE, et al. Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke. 1992;23(5):632–40.PubMedCrossRefGoogle Scholar
  10. 10.
    Haley EC, Levy DE, Brott TG, et al. Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke. 1992;23(5):641–5.PubMedCrossRefGoogle Scholar
  11. 11.
    NINDS tPA Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581–7.CrossRefGoogle Scholar
  12. 12.
    Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017–25.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998;352:1245–51.PubMedCrossRefGoogle Scholar
  14. 14.
    Albers GW, Clark WM, Madden KP, Hamilton SA. ATLANTIS trial: results for patients treated within 3 hours of stroke onset. Alteplase thrombolysis for acute noninterventional therapy in ischemic stroke. Stroke. 2002;33:493–5.PubMedCrossRefGoogle Scholar
  15. 15.
    Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase thrombolysis for acute noninterventional therapy in ischemic stroke. JAMA. 1999;282:2019–26.PubMedCrossRefGoogle Scholar
  16. 16.
    Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317–29.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, Murray G, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet. 2012;379(9834):2352–63.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Wardlaw JM, Murray V, Berge E, del Zoppo GJ. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2014;7(7):CD000213.PubMedCentralGoogle Scholar
  19. 19.
    Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, et al. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018;49(3):e46–110.PubMedCrossRefGoogle Scholar
  20. 20.
    Campbell BCV, Mitchell PJ, Churilov L, et al. Tenectaplase versus alteplase before thrombectomy for ischemic stroke. N Engl J Med. 2018;378:1573–82.PubMedCrossRefGoogle Scholar
  21. 21.
    National Institute of Health, National Institute of Neurological Disorders and Stroke. NIH stroke scale. https://www.ninds.nih.gov/sites/default/files/NIH_Stroke_Scale_Booklet.pdf. Accessed 11 May 2018.
  22. 22.
    Demchuk AM, Khan F, Hill MD, Barber PA, Silver B, Patel S, Levine SR, NINDS rt-PA Stroke Study Group. Importance of leukoaraiosis on CT for tissue plasminogen activator decision making: evaluation of the NINDS rt-PA Stroke Study. Cerebrovasc Dis. 2008;26:120–5.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Dzialowski I, Hill MD, Coutts SB, Demchuk AM, Kent DM, Wunderlich O, von Kummer R. Extent of early ischemic changes on computed tomography (CT) before thrombolysis: prognostic value of the Alberta stroke program early CT score in ECASS II. Stroke. 2006;37:973–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Demchuk AM, Hill MD, Barber PA, Silver B, Patel SC, Levine SR, for the NINDS rtPA Stroke Study Group, NIH. Importance of early ischemic computed tomography changes using ASPECTS in NINDS rtPA Stroke Study. Stroke. 2005;36:2110–5.PubMedCrossRefGoogle Scholar
  25. 25.
    Patel SC, Levine SR, Tilley BC, Grotta JC, Lu M, Frankel M, Haley EC Jr, Brott TG, Broderick JP, Horowitz S, Lyden PD, Lewandowski CA, Marler JR, Welch KM, National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. JAMA. 2001;286:2830–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Rost NS, Masrur S, Pervez MA, Viswanathan A, Schwamm LH. Unsuspected coagulopathy rarely prevents IV thrombolysis in acute ischemic stroke. Neurology. 2009;73:1957–62.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Cucchiara BL, Jackson B, Weiner M, Messe SR. Usefulness of checking platelet count before thrombolysis in acute ischemic stroke. Stroke. 2007;38:1639–40.PubMedCrossRefGoogle Scholar
  28. 28.
    James P, Ellis CJ, Whitlock RM, McNeil AR, Henley J, Anderson NE. Relation between troponin T concentration and mortality in patients presenting with an acute stroke: observational study. BMJ. 2000;320:1502–4.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Jensen JK, Kristensen SR, Bak S, Atar D, Høilund-Carlsen PF, Mickley H. Frequency and significance of troponin T elevation in acute ischemic stroke. Am J Cardiol. 2007;99:108–12.PubMedCrossRefGoogle Scholar
  30. 30.
    Demchuk AM. Yes, intravenous thrombolysis should be administered in pregnancy when other clinical and imaging factors are favorable. Stroke. 2013;44:864–5.PubMedCrossRefGoogle Scholar
  31. 31.
    Saber H, Silver B, Santillan A, Azarpazhooh MR, Misra V, Behrouz R. Role of emergent chest radiography in evaluation of hyperacute stroke. Neurology. 2016;87:782–5.PubMedCrossRefGoogle Scholar
  32. 32.
    Lima FO, Lev MH, Levy RA, Silva GS, Ebril M, de Camargo EC, Pomerantz S, Singhal AB, Greer DM, Ay H, González RG, Koroshetz WJ, Smith WS, Furie KL. Functional contrast-enhanced CT for evaluation of acute ischemic stroke does not increase the risk of contrastinduced nephropathy. AJNR Am J Neuroradiol. 2010;31:817–21.PubMedCrossRefGoogle Scholar
  33. 33.
    Hopyan JJ, Gladstone DJ, Mallia G, Schiff J, Fox AJ, Symons SP, Buck BH, Black SE, Aviv RI. Renal safety of CT angiography and perfusion imaging in the emergency evaluation of acute stroke. AJNR Am J Neuroradiol. 2008;29:1826–30.PubMedCrossRefGoogle Scholar
  34. 34.
    Krol AL, Dzialowski I, Roy J, Puetz V, Subramaniam S, Coutts SB, Demchuk AM. Incidence of radiocontrast nephropathy in patients undergoing acute stroke computed tomography angiography. Stroke. 2007;38:2364–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med. 2018;378(1):11–21.PubMedCrossRefGoogle Scholar
  36. 36.
    Albers GW, Marks MP, Kemp S, Christensen S, Tsai JP, Ortega-Gutierrez S, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med. 2018;378(8):708–18.PubMedCrossRefGoogle Scholar
  37. 37.
    Vemmos KN, Spengos K, Tsivgoulis G, Zakopoulos N, Manios E, Kotsis V, et al. Factors influencing acute blood pressure values in stroke subtypes. J Hum Hypertens. 2004;18:253–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Ahmed N, Wahlgren N, Brainin M, Castillo J, Ford GA, Kaste M, Lees KR, Toni D, SITS Investigators. Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis. Retrospective analysis from safe implementation of thrombolysis in stroke-international stroke thrombolysis register (SITS-ISTR). Stroke. 2009;40:2442–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Butcher K, Christensen S, Parsons M, De Silva DA, Ebinger M, Levi C, et al. Postthrombolysis blood pressure elevation is associated with hemorrhagic transformation. Stroke. 2010;41:72–7.PubMedCrossRefGoogle Scholar
  40. 40.
    Perini F, De Boni A, Marcon M, Bolgan I, Pellizzari M, Dionisio LD. Systolic blood pressure contributes to intracerebral haemorrhage after thrombolysis for ischemic stroke. J Neurol Sci. 2010;297:52–4.PubMedCrossRefGoogle Scholar
  41. 41.
    Cronin CA, Sheth KN, Zhao X, Messé SR, Olson DM, Hernandez AF, et al. Adherence to third European cooperative acute stroke study 3- to 4.5-hour exclusions and association with outcome: data from get with the guidelines-stroke. Stroke. 2014;45:2745–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Mishra NK, Ahmed N, Davalos A, Iversen HK, Melo T, Soinne L, et al. Thrombolysis outcomes in acute ischemic stroke patients with prior stroke and diabetes mellitus. Neurology. 2011;77:1866–72.PubMedCrossRefGoogle Scholar
  43. 43.
    Xian Y, Federspiel JJ, Grau-Sepulveda M, Hernandez AF, Schwamm LH, Bhatt DL, et al. Risks and benefits associated with prestroke antiplatelet therapy among patients with acute ischemic stroke treated with intravenous tissue plasminogen activator. JAMA Neurol. 2016;73:50–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Luo S, Zhuang M, Zeng W, Tao J. Intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy: a systematic review and meta-analysis of 19 studies. J Am Heart Assoc. 2016;5(5):e003242.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Pan X, Zhu Y, Zheng D, Liu Y, Yu F, Yang J. Prior antiplatelet agent use and outcomes after intravenous thrombolysis with recombinant tissue plasminogen activator in acute ischemic stroke: a meta-analysis of cohort studies and randomized controlled trials. Int J Stroke. 2015;10:317–23.PubMedCrossRefGoogle Scholar
  46. 46.
    Hao Z, Yang C, Liu M, Wu B. Renal dysfunction and thrombolytic therapy in patients with acute ischemic stroke: a systematic review and meta-analysis. Medicine (Baltimore). 2014;93(28):e286.CrossRefGoogle Scholar
  47. 47.
    Na DG, Sohn CH, Kim EY. Imaging-based management of acute ischemic stroke patients: current neuroradiological perspectives. Korean J Radiol. 2015;16:372–90.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Demaerschalk BM, Kleindorfer DO, Adeoye OM, Demchuk AM, Fugate JE, Grotta JC, et al. Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2016;47:581–641.PubMedCrossRefGoogle Scholar
  49. 49.
    Adams RJ, Cox M, Ozark SD, Kanter J, Schulte PF, Xian Y, et al. Coexistent sickle cell disease has no impact on the safety and outcome of lytic therapy in acute ischemic stroke. Stroke. 2017;48:686–91.PubMedCrossRefGoogle Scholar
  50. 50.
    White-Bateman SR, Schumacher HC, Sacco RL, Appelbaum PS. Consent for intravenous thrombolysis in acute stroke: review and future directions. Arch Neurol. 2007;64:785–92.PubMedCrossRefGoogle Scholar
  51. 51.
    Miller DJ, Simpson JR, Silver B. Safety of thrombolysis in acute ischemic stroke: a review of complications, risk factors, and newer technologies. Neurohospitalist. 2011;1(3):138–47.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    The NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke. 1997;28(11):2109–18.CrossRefGoogle Scholar
  53. 53.
    Kase CS, Furlan AJ, Wechsler LR, et al. Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke: the PROACT II trial. Neurology. 2001;57(9):1603–10.PubMedCrossRefGoogle Scholar
  54. 54.
    Tanne D, Kasner SE, Demchuk AM, et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA stroke survey. Circulation. 2002;105(14):1679–85.PubMedCrossRefGoogle Scholar
  55. 55.
    Wahlgren N, Ahmed N, Eriksson N, et al. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: safe implementation of thrombolysis in stroke-MOnitoring STudy (SITS-MOST). Stroke. 2008;39(12):3316–22.PubMedCrossRefGoogle Scholar
  56. 56.
    Cucchiara B, Kasner SE, Tanne D, et al. Factors associated with intracerebral hemorrhage after thrombolytic therapy for ischemic stroke: pooled analysis of placebo data from the stroke-acute ischemic NXY treatment (SAINT) I and SAINT II trials. Stroke. 2009;40(9):3067–72.PubMedCrossRefGoogle Scholar
  57. 57.
    Lansberg MG, Albers GW, Wijman CA. Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors. Cerebrovasc Dis. 2007;24(1):1–10.PubMedCrossRefGoogle Scholar
  58. 58.
    French KF, White J, Hoesch RE. Treatment of intracerebral hemorrhage with tranexamic acid after thrombolysis with tissue plasminogen activator. Neurocrit Care. 2012;17:107–11.PubMedCrossRefGoogle Scholar
  59. 59.
    Yaghi S, Eisenberger A, Willey JZ. Symptomatic intracerebral hemorrhage in acute ischemic stroke after thrombolysis with intravenous recombinant tissue plasminogen activator: a review of natural history and treatment. JAMA Neurol. 2014;71:1181–5.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Rudolf J, Grond M, Schmulling S, Neveling M, Heiss W. Orolingual angioneurotic edema following therapy of acute ischemic stroke with alteplase. Neurology. 2000;55(4):599–600.PubMedCrossRefGoogle Scholar
  61. 61.
    Hill MD, Lye T, Moss H, et al. Hemi-orolingual angioedema and ACE inhibition after alteplase treatment of stroke. Neurology. 2003;60(9):1525–7.PubMedCrossRefGoogle Scholar
  62. 62.
    O’Carroll CB, Aguilar MI. Management of postthrombolysis hemorrhagic and orolingual angioedema complications. Neurohospitalist. 2015;5:133–41.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Myslimi F, Caparros F, Dequatre-Ponchelle N, Moulin S, Gautier S, Girardie P, et al. Orolingual angioedema during or after thrombolysis for cerebral ischemia. Stroke. 2016;47:1825–30.PubMedCrossRefGoogle Scholar
  64. 64.
    Pahs L, Droege C, Kneale H, Pancioli A. A novel approach to the treatment of orolingual angioedema after tissue plasminogen activator administration. Ann Emerg Med. 2016;68:345–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Vasudha Singhal
    • 1
  • Jaya Wanchoo
    • 1
  1. 1.Department of Neuroanesthesiology and Critical CareMedanta, The MedicityGurgaonIndia

Personalised recommendations